A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2014
At a glance
- Drugs Tivozanib (Primary)
- Indications Breast cancer; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Renal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors AVEO Oncology
- 23 Jan 2014 Status changed to completed as per ClinicalTrials.gov record.
- 13 Jun 2013 Planned End Date changed from 1 Apr 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned End Date changed from 1 Jan 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.